Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?

Tini, Giacomo; Sarocchi, Matteo; Ameri, Pietro; Battistoni, Allegra; Arboscello, Eleonora; Spallarossa, Paolo; Porto, Italo

doi:10.2459/jcm.0000000000001346

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients scheduled to receive VEGF inhibitors, this score seems to overestimate the risk of cardiovascular toxicities in cancer patients 13 …”

Section: Introductionmentioning

confidence: 99%

“…12 In patients scheduled to receive VEGF inhibitors, this score seems to overestimate the risk of cardiovascular toxicities in cancer patients. 13 A subanalysis of the CARDIOTOX registry showed a good ability of the HFA/ICOS score to predict all-cause mortality and cardiotoxicity in patients treated with anthracyclines. 14 Therefore, considering the little evidence in the literature about the validity of the HFA/ICOS score in clinical practice, our study aimed to assess the clinical application of this score in breast cancer patients undergoing chemotherapy and its usefulness in predicting the development of CTRCD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer

Di Lisi,

Madaudo,

Faro

et al. 2024

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Background The 2022 ESC Guidelines on Cardio-Oncology recommend baseline cardiovascular risk stratification before starting anticancer drugs, using the new risk assessment tools proposed by the Heart Failure Association (HFA) and the International Cardio-Oncology Society (ICOS). Our study aimed to assess the clinical application of HFA/ICOS risk score in breast cancer patients undergoing chemotherapy and its usefulness in predicting the development of chemotherapy-related cardiac dysfunction (CTRCD). Methods A prospective multicentric study enrolled 109 breast cancer patients treated with anthracyclines with or without trastuzumab. A cardiological evaluation, including ECG and echocardiogram at baseline (T0), 3 (T1), 6 (T2), and 12 months (T3) after starting treatment was performed. HFA/ICOS score was assessed in all patients; the population was divided into low, medium, high, and very-high risk. During follow-up, CTRCD and other cardiovascular events have been evaluated. Results Sixty-one patients met low risk, 37 medium, nine high, two very-high risk criteria. We found a significantly higher incidence of overall cardiotoxicity (CTRCD and other cardiovascular events) in the very-high risk group (100%) compared with the medium (29%) and low risk groups (13%). CTRCD incidence was also significantly higher in the high risk group (55%). CTRCD resulted as being associated with baseline arterial hypertension and baseline HFA/ICOS risk score of high (P = 0.006) or very-high (P < 0.0001). Conclusion Our study confirms the HFA/ICOS score's ability to predict cardiovascular toxicity in breast cancer women and the need for close monitoring especially in high and very-high risk patients.

show abstract

“…In patients scheduled to receive VEGF inhibitors, this score seems to overestimate the risk of cardiovascular toxicities in cancer patients 13 …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer

Di Lisi,

Madaudo,

Faro

et al. 2024

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers

Di Lisi,

Cadeddu Dessalvi,

Zito

et al. 2024

Current Problems in Cardiology

View full text Add to dashboard Cite

Does the HFA/ICOS tool overestimate the risk of cardiovascular toxicities in oncologic patients scheduled to receive anti-VEGF agents?

Cited by 2 publications

References 8 publications

The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer

The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer

Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers

Contact Info

Product

Resources

About